500660 Stock Overview
Manufactures, distributes, and trades in pharmaceuticals in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
GlaxoSmithKline Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,909.25 |
| 52 Week High | ₹3,087.95 |
| 52 Week Low | ₹1,877.70 |
| Beta | 0.13 |
| 1 Month Change | 1.70% |
| 3 Month Change | 41.07% |
| 1 Year Change | 55.67% |
| 3 Year Change | 82.22% |
| 5 Year Change | 100.02% |
| Change since IPO | 2,373.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 500660 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.9% | 3.7% | 4.3% |
| 1Y | 55.7% | 15.3% | 3.4% |
Return vs Industry: 500660 exceeded the Indian Pharmaceuticals industry which returned 15.3% over the past year.
Return vs Market: 500660 exceeded the Indian Market which returned 3.4% over the past year.
Price Volatility
| 500660 volatility | |
|---|---|
| 500660 Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.9% |
Stable Share Price: 500660 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 500660's weekly volatility (8%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1924 | 3,211 | Bhushan Akshikar | india-pharma.gsk.com |
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease.
GlaxoSmithKline Pharmaceuticals Limited Fundamentals Summary
| 500660 fundamental statistics | |
|---|---|
| Market cap | ₹492.84b |
| Earnings (TTM) | ₹8.59b |
| Revenue (TTM) | ₹37.05b |
57.4x
P/E Ratio13.3x
P/S RatioIs 500660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500660 income statement (TTM) | |
|---|---|
| Revenue | ₹37.05b |
| Cost of Revenue | ₹14.27b |
| Gross Profit | ₹22.78b |
| Other Expenses | ₹14.19b |
| Earnings | ₹8.59b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 13, 2025
| Earnings per share (EPS) | 50.72 |
| Gross Margin | 61.49% |
| Net Profit Margin | 23.19% |
| Debt/Equity Ratio | 0.9% |
How did 500660 perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield92%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/19 13:49 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GlaxoSmithKline Pharmaceuticals Limited is covered by 25 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shirish Pardeshi | Anand Rathi Shares and Stock Brokers Limited |
| Sarabjit Nangra | Angel Broking Private Limited |
| Prakash Agarwal | Axis Capital Limited |